Experts offered pointers on appropriate use of iron therapies, erythropoiesis stimulating agents (ESAs), and hypoxia inducible factor inhibitors (HIF-PHI) for anemia of chronic kidney disease (CKD).

Please provide your email address to receive an email when new articles are posted on . Patients switched to oral vadadustat had hemoglobin levels similar to those on a long-acting ...

Treatment with vadadustat was noninferior to darbepoetin alfa in correcting and maintaining Hb levels in adults with incident dialysis-dependent CKD. The Food and Drug Administration (FDA) has ...

Ziltivekimab, an anti-IL-6 ligand antibody, increases iron and other anemia parameters in patients with chronic kidney disease (CKD). Ziltivekimab, a novel anti-IL-6 ligand antibody, improves ...

With the skyrocketing popularity of GLP-1 RAs, some lesser-known side effects, including anemia, are coming to light.

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns ...

Anemia resulting from cancer, or its treatment, and from chronic kidney disease (CKD) is an important clinical problem. Evidence suggests that in patients with CKD (especially those on dialysis), ...

In the decades since the human genome was first sequenced, scientists have repeatedly and boldly declared that “the concept of race has no genetic or scientific basis.” 1 Yet medical and research ...